US researchers have revealed(link is external) the identity of molecules on the surface of cancer cells which allow the body’s immune system to identify and destroy them.
The research could lead to a new generation of immunotherapies that are far more effective than those currently in use, that could target a range of cancers.
“This is a huge breakthrough,” said Cancer Research UK’s Dr Sergio Quezada, who works at UCL in London and was not involved in the research.
“The researchers were looking for ‘signatures’ on the surface of cancer cells associated with response to current immunotherapies, but their findings go further than that. They’ve actually discovered molecular motifs that will inform the development of the next generation of therapies,” he added.
The researchers, led by a team at the Memorial Sloan Kettering Cancer Centre in New York, analysed cancer DNA from 64 melanoma patients who had been treated with an immunotherapy drug called ipilimumab, half of whom had responded to the drug.
Ipilimumab works by switching on the body’s immune system to attack their cancer, but – for unknown reasons – it only works effectively in a minority of patients.
“We’ve been using a drug that empirically was found to be quite effective, and yet we didn’t have a detailed understanding of how it was working in people,” said Memorial Sloan Kettering’s Dr Jedd Wolchok.
Having analysed the patients’ cancer DNA, the researchers used sophisticated software to look for genetic mutations in the cancer cells that could predict whether patients had, or hadn’t, responded to the drug.
In doing so, they uncovered a series of genetic mutations in some of the patients that caused the cancer cells to produce short stretches of protein molecules, called peptide antigens, that make cancerous cells visible to immune response.
Tantalisingly, it appears that these mutations cause the antigens to mimic small parts of proteins produced by bacteria and viruses, explaining why they are so effective at triggering the immune response – although the researchers say more research will be needed to confirm this.
The discovery is “big, big news” for immunotherapy researchers says Cancer Research UK’s Dr Quezada. “This is the first time we’ve had an idea of what the immune system actually ‘sees’ on a tumour. Until now, it’s been hot topic of debate,” he said.
The Latest on: Immunotherapies
via Google News
The Latest on: Immunotherapies
- Ludwig Cancer Research study develops a safer CAR-T therapyon February 3, 2020 at 8:47 pm
A Ludwig Cancer Research study has devised a new type of chimeric antigen-receptor (CAR) T cell-;a family of promising immunotherapies for cancer- that can be switched on and off on demand. The study, ...
- Math models add up to improved cancer immunotherapyon February 3, 2020 at 12:01 pm
A merger of math and medicine may help to improve the efficacy of immunotherapies, potentially life-saving treatments that enhance the ability of the patient's own immune system to attack cancerous ...
- Designing an emergency stop switch for immunotherapieson February 3, 2020 at 10:01 am
Immunotherapy, unlike chemotherapy and radiotherapy, arms the body's immune system to attack cancer cells. In recent years, it has proven to be remarkably successful at treating leukemia, lymphoma and ...
- Cheap nanoparticles stimulate immune response to cancer in the labon February 3, 2020 at 9:43 am
They are cheaper to produce and easier to engineer than the antibodies that underlie current immunotherapies, which as drugs cost tens of thousands of dollars a month. "Immunotherapy basically boosts ...
- Single-cell genomic approaches for developing the next generation of immunotherapieson February 3, 2020 at 8:29 am
Recent progress in single-cell genomics urges its application in drug development, particularly of cancer immunotherapies. Current immunotherapy pipelines are focused on functional outcome and simple ...
- Survey Confirms Physician Interest in Peanut Allergy Immunotherapyon February 3, 2020 at 5:04 am
“These survey findings are encouraging as we see peanut allergy immunotherapies progress toward FDA approval,” said Michael Nelson, CEO, Intrommune. “The FDA’s approval of an oral immunotherapy for ...
- OncoSec's Visceral Lesion Applicator (VLA)...on February 3, 2020 at 4:46 am
SAN DIEGO and PENNINGTON, N.J., Feb. 3, 2020 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today ...
- Calidi Biotherapeutics Announces Abstract Acceptance for Presentation at the ASCO-SITC Clinical Immuno-Oncology Symposiumon February 3, 2020 at 1:00 am
SAN DIEGO--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced the ...
- Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officeron February 3, 2020 at 12:00 am
Dr. Lindmark brings broad R&D expertise, particularly in respiratory and inflammation Appointment reinforces Galecto's ambition to be a global ...
- CAR T treatments could have fewer side effects than other cancer immunotherapieson January 29, 2020 at 6:28 am
New cancer immunotherapies involve extracting a patient's T cells and genetically engineering them so they will recognize and attack tumors. This technique is a true medical breakthrough, with an ...
via Bing News